Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
نویسندگان
چکیده
منابع مشابه
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
PURPOSE Arthralgia is the most common side effect in breast cancer patients receiving aromatase inhibitor (AI) therapy. Few studies have evaluated the risk factors, onset, and incidence of musculoskeletal pain in these patients. This study identifies the risk factors of AI-related severe arthralgia and their prevalence. METHODS All the clinical and pathological records of postmenopausal patie...
متن کاملAromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
The introduction of aromatase inhibitor (AI) therapy for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer has led to a significant change in the management of the disease. AIs are slightly more efficacious and initially appeared to have a better toxicity profile compared to the previous gold standard, tamoxifen. However, increased use of AIs in the com...
متن کاملPilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms.
BACKGROUND Approximately 50% of postmenopausal women with hormone receptor-positive early stage breast cancer treated with an aromatase inhibitor (AI) develop musculoskeletal symptoms. Standard analgesics are relatively ineffective. Duloxetine is a serotonin norepinephrine reuptake inhibitor with proven efficacy for treatment of multiple chronic pain states. The authors investigated the hypothe...
متن کاملEtiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms.
Aromatase inhibitors (AIs) are recommended as adjuvant endocrine therapy for postmenopausal women with hormone-responsive breast cancer. With the widespread use of AI adjuvant endocrine therapy, a significant profile of musculoskeletal symptoms has emerged. Moderate to severe musculoskeletal symptoms have led some women to discontinue therapy, compromising the survival benefit. The etiology of ...
متن کاملAromatase inhibitor-associated bone loss.
273 A 49-year-old postmenopausal Caucasian woman named M.A. was diagnosed with estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-negative breast cancer. Anthracycline and taxane-based adjuvant chemotherapy and radiation therapy were followed by adjuvant therapy with an aromatase inhibitor (AI). Before M.A. started adjuvant AI therapy, she was evaluated for any additiona...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Korean Surgical Society
سال: 2013
ISSN: 2233-7903,2093-0488
DOI: 10.4174/jkss.2013.85.5.205